医药领域专利合作条约申请现状及策略  

Situation and Strategy of Pharmaceutical PCT Patent Applications

作　　者：欧阳雪宇[1] 何杰[1] 马秋娟[1] 闫寒[1] 陈红霞[1] 

机构地区：[1]国家知识产权局专利局专利审查协作北京中心医药生物部,北京100190

出　　处：《中国药学杂志》2014年第14期1274-1278,共5页Chinese Pharmaceutical Journal

摘　　要：目的介绍专利合作条约（PCT）申请的定义和优点，分析医药领域专利合作条约申请的现状和策略。方法以2003-2012年医药领域由中国专利局（SIPO）受理的专利合作条约申请作为研究对象，分析申请量、申请人和领域分布情况，以及进入中国专利局、欧洲专利局（EPO）、美国专利商标局（USPTO）和日本专利局（JPO）四局的审查情况。结果2003-2012年医药领域专利合作条约申请的数量在逐年增加，其中公司是申请主力，专利合作条约申请在不同国家的审查结果不尽相同，其中中国专利局授权率最高，美国专利商标局授权率最低。结论提出一些医药领域专利合作条约申请的可操作策略。OBJECTIVE To introduce the definition and advantage of PCT patent application, and to analyze the situation and strategy of pharmaceutical PCT patent applications. METHODS The quantity, applicant and field distribution of 2003 -2012 pharmaceutical PCT patent applications accepted by SIPO and the examination result in SIPO, EPO, USPTO and JPO were analyzed. RESULTS The quantity of 2003 -2012 pharmaceutical PCT patent applications is increased year by year. Company is the most popular applicant. The examination results of the applications are different after they entered in different countries, and the authorized rate is highest in SIPO and lowest in USPTO. CONCLUSION Operable strategies are proposed.

关 键 词：医药领域 专利合作条约申请 专利分析 

分 类 号：R95[医药卫生—药学]